Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-11-26 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
CONTINUING CONNECTED TRANSACTION CDMO SERVICES FRAMEWORK AGREEMENT
Regulatory Filings Classification · 90% confidence The document is an announcement issued on the Hong Kong Stock Exchange regarding a continuing connected transaction (CDMO Services Framework Agreement) and the convening of an Extraordinary General Meeting (EGM) for shareholder approval under the Listing Rules. It details the transaction terms, listing rule implications, independent board committee, and the EGM notice, but it is not the full shareholder circular or proxy statement itself—it simply announces the transaction and EGM. This type of miscellaneous regulatory disclosure that does not fit into a more specific category is classified as a general regulatory filing (RNS).
2024-11-26 English
ANNOUNCEMENT OF PROPOSED CHANGE OF AUDITOR
Regulatory Filings Classification · 85% confidence The document is a corporate announcement made under the Listing Rules of the Hong Kong Stock Exchange regarding the proposed resignation of the existing auditor (PwC) and the proposed appointment of a new auditor (Ernst & Young). It does not contain an actual audit report or financial statements, nor is it an AGM presentation, earnings release, or management discussion. It is a standalone announcement related to auditor change, which does not fit any of the more specific categories, so it falls under the general “Regulatory Filings” category (RNS).
2024-11-26 English
CONTINUING CONNECTED TRANSACTION NEW PROCUREMENT FRAMEWORK AGREEMENT
Regulatory Filings Classification · 85% confidence The document is an announcement filed on the HKEX relating to a new continuing connected transaction framework agreement for procurement between the company and a connected party under Chapter 14A of the Listing Rules. It is a regulatory disclosure detailing the terms, annual caps, pricing policies, internal controls, and implications under the Listing Rules. It does not constitute a financial report, earnings release, annual report, or investor presentation, nor does it involve share issuance, dividends, or management changes. Therefore, it is best classified as a general regulatory filing under the fallback category.
2024-11-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, and confirms compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and share movement information. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing of share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS).
2024-11-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and share movement information. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing of share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS).
2024-10-07 English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION AND PRIORITY REVIEW GRANTED BY NMPA TO MRG003 FOR THE TREATMENT OF R/M NPC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Lepu Biopharma Co., Ltd. regarding the acceptance of a New Drug Application (NDA) and priority review granted by the China National Medical Products Administration (NMPA) for a drug candidate MRG003. It discusses regulatory milestones and potential impact on the company but does not contain financial statements, detailed financial data, or comprehensive report content. The document length is 3957 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is an annual report, interim report, earnings release, or any other detailed financial or governance report. It is clearly an announcement of a regulatory event related to drug approval. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.